Iron Overload May Promote Alteration of NK Cells and Hematopoietic Stem/progenitor Cells by JNK and P38 Pathway in Myelodysplastic Syndromes

Overview

Journal Int J Hematol

Specialty Hematology

Date 2017 Apr 14

PMID 28405919

Citations 7

Authors

Yanni Hua

Chaomeng Wang

Huijuan Jiang

Yihao Wang

Chunyan Liu

Lijuan Li

Hui Liu

Zonghong Shao

Rong Fu

Affiliations

Soon will be listed here.

Abstract

The objective of the study was to examine levels of intracellular iron, reactive oxygen species (ROS) and the expression of JNK and p38MAPK in NK cells and hematopoietic stem/progenitor cells (HSPCs) in MDS patients, and explore potential mechanisms by which iron overload (IOL) promotes MDS progression. Thirty-four cases of MDS and six cases of AML transformed from MDS (MDS/AML) were included. HSPCs and NK cells were isolated by magnetic absorption cell sorting. We used flow cytometry to detect the levels of ROS and intracellular JNK and P38 in NK cells and HSPCs. Total RNA and protein were extracted from NK cells and CD34 cells to examine the expression of JNK and p38MAPK using RT-PCR and Western blotting. Intracellular iron concentration was detected. Data were analyzed by SPSS 21 statistical software. Intracellular iron concentration and ROS were increased in both NK cells and HSPCs in MDS patients with iron overload (P < 0.05). MDS patients with iron overload had higher JNK expression and lower p38 expression in NK cells, and higher p38 expression in HSPCs compared with non-iron overload group. IOL may cause alterations in NK cells and HSPCs through the JNK and p38 pathways, and play a role in the transformation to AML from MDS.

Citing Articles

Unveiling the role of lncRNA ERDR1 in immune cell regulation.

Shu A, Tian X, Yue J, Jiang Y, Liu Y Heliyon. 2025; 11(3):e42085.

PMID: 39991241 PMC: 11847233. DOI: 10.1016/j.heliyon.2025.e42085.

A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.

Arellano-Ballestero H, Sabry M, Lowdell M Cells. 2023; 12(4).

PMID: 36831300 PMC: 9954109. DOI: 10.3390/cells12040633.

Nutritional immunity: the impact of metals on lung immune cells and the airway microbiome during chronic respiratory disease.

Healy C, Munoz-Wolf N, Strydom J, Faherty L, Williams N, Kenny S Respir Res. 2021; 22(1):133.

PMID: 33926483 PMC: 8082489. DOI: 10.1186/s12931-021-01722-y.

Effects of signaling pathway inhibitors on hematopoietic stem cells.

Jiang Y, Xu Z, Ma N, Yin L, Hao C, Li J Mol Med Rep. 2020; 23(1).

PMID: 33179097 PMC: 7687261. DOI: 10.3892/mmr.2020.11647.

[Research progress of characteristics and mechanisms of iron overload affecting bone marrow hematopoiesis].

Huang L, Fu R Zhonghua Xue Ye Xue Za Zhi. 2019; 40(8):709-712.

PMID: 31495147 PMC: 7342874. DOI: 10.3760/cma.j.issn.0253-2727.2019.08.021.

References

Rose C, Brechignac S, Vassilief D, Pascal L, Stamatoullas A, Guerci A . Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM (Groupe Francophone des Myélodysplasies). Leuk Res. 2010; 34(7):864-70. DOI: 10.1016/j.leukres.2009.12.004. View

Goldberg S, Chen E, Corral M, Guo A, Mody-Patel N, Pecora A . Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol. 2010; 28(17):2847-52. DOI: 10.1200/JCO.2009.25.2395. View

Gattermann N, Rachmilewitz E . Iron overload in MDS-pathophysiology, diagnosis, and complications. Ann Hematol. 2010; 90(1):1-10. DOI: 10.1007/s00277-010-1091-1. View

Lyons R, Marek B, Paley C, Esposito J, Garbo L, DiBella N . Comparison of 24-month outcomes in chelated and non-chelated lower-risk patients with myelodysplastic syndromes in a prospective registry. Leuk Res. 2013; 38(2):149-54. DOI: 10.1016/j.leukres.2013.11.004. View

Deb S, Johnson E, Robalinho-Teixeira R, Wessling-Resnick M . Modulation of intracellular iron levels by oxidative stress implicates a novel role for iron in signal transduction. Biometals. 2009; 22(5):855-62. PMC: 2915439. DOI: 10.1007/s10534-009-9214-7. View

Huang C, Huang K, Wang C, Jiang Z, Li X, Wang H . Overexpression of mitogen-activated protein kinase kinase 4 and nuclear factor-kappaB in laryngeal squamous cell carcinoma: a potential indicator for poor prognosis. Oncol Rep. 2009; 22(1):89-95. View

Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K . Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes. Leuk Res. 2014; 38(5):557-63. DOI: 10.1016/j.leukres.2014.02.003. View

Takatoku M, Uchiyama T, Okamoto S, Kanakura Y, Sawada K, Tomonaga M . Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007; 78(6):487-94. DOI: 10.1111/j.1600-0609.2007.00842.x. View

Mi H, Fu R, Wang H, Qu W, Ruan E, Wang X . [Changes of natural kill cell in peripheral blood of patients with myelodysplastic syndrome]. Zhonghua Yi Xue Za Zhi. 2014; 94(10):737-41. View

10.

Malcovati L, Della Porta M, Pascutto C, Invernizzi R, Boni M, Travaglino E . Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005; 23(30):7594-603. DOI: 10.1200/JCO.2005.01.7038. View

11.

Cazzola M, Malcovati L . Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Engl J Med. 2005; 352(6):536-8. DOI: 10.1056/NEJMp048266. View

12.

Finegan K, Tournier C . The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer. Cancer Res. 2010; 70(14):5797-806. PMC: 2906708. DOI: 10.1158/0008-5472.CAN-09-3669. View

13.

Antosiewicz J, Ziolkowski W, Kaczor J, Herman-Antosiewicz A . Tumor necrosis factor-alpha-induced reactive oxygen species formation is mediated by JNK1-dependent ferritin degradation and elevation of labile iron pool. Free Radic Biol Med. 2007; 43(2):265-70. DOI: 10.1016/j.freeradbiomed.2007.04.023. View

14.

Teng D, Perry 3rd W, Hogan J, Baumgard M, Bell R, Berry S . Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res. 1997; 57(19):4177-82. View

15.

Yu Y, Richardson D . Cellular iron depletion stimulates the JNK and p38 MAPK signaling transduction pathways, dissociation of ASK1-thioredoxin, and activation of ASK1. J Biol Chem. 2011; 286(17):15413-27. PMC: 3083220. DOI: 10.1074/jbc.M111.225946. View

16.

Wilkinson M, Millar J . Control of the eukaryotic cell cycle by MAP kinase signaling pathways. FASEB J. 2000; 14(14):2147-57. DOI: 10.1096/fj.00-0102rev. View

17.

Cherayil B . Iron and immunity: immunological consequences of iron deficiency and overload. Arch Immunol Ther Exp (Warsz). 2010; 58(6):407-15. PMC: 3173740. DOI: 10.1007/s00005-010-0095-9. View

18.

Pearson G, Robinson F, Beers Gibson T, Xu B, Karandikar M, Berman K . Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001; 22(2):153-83. DOI: 10.1210/edrv.22.2.0428. View

19.

Lee J, Khor T, Shu L, Su Z, Fuentes F, Kong A . Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. Pharmacol Ther. 2012; 137(2):153-71. PMC: 3694988. DOI: 10.1016/j.pharmthera.2012.09.008. View

20.

Jian J, Yang Q, Dai J, Eckard J, Axelrod D, Axelrod D . Effects of iron deficiency and iron overload on angiogenesis and oxidative stress-a potential dual role for iron in breast cancer. Free Radic Biol Med. 2011; 50(7):841-7. PMC: 3046244. DOI: 10.1016/j.freeradbiomed.2010.12.028. View